Stockscreener 앱 받기
17.24
0.23%
-0.04
시간 외 거래:
17.25
0.01
+0.06%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
PFE5282056 Bond Profile — Key Metrics - TradingView
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris’ Quarterly Earnings Preview: What You Need to Know - Inkl
Viatris, Inc. (VIA) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
PFE5003242 Bond Profile — Key Metrics - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon - BW Legal World
Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership? - Sahm
Viatris stock hits 52-week high at $17.54 By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at $17.54 - Investing.com UK
Khaitan & Co, JSA, TT&A, Baker & McKenzie act on Viatris Inc's ₹3,680 crore exit from Biocon - Bar and Bench
PFE5282058 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Looks to New Launches and Cost Savings for Long-Term Growth - Morningstar
XS332542958 Bond Profile — Key Metrics - TradingView
ETFs Investing in Viatris, Inc. Stocks - TradingView
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows - WTVB
Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon - Business Standard
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
(VTRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viatris shares break six-session winning streak - MSN
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS) - simplywall.st
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - AOL.com
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Refinances $247.7 Million Term Loan - Moomoo
VTRSViatris Inc Dividends - Finviz
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris to Report Second-Quarter 2026 Financial Results on Augus - GuruFocus
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris Inc Enters Into Amended and Restated Term Loan Credit Agreement for JPY 40,000,000,000 Senior Unsecured Term Loan Facility - marketscreener.com
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025Contact Levi & Korsinsky - The National Law Review
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
0.93%
0.20%
자본화:
|
볼륨(24시간):